argenx agreed on Monday to buy Forte Biosciences for $77 a share in cash, about $2.2 billion, and the number that frames the whole deal is not the headline price. It is the premium. The offer is roughly 41% above Forte's closing price on Friday, but about 86% above Forte's average price since July 9, the day Forte reported positive early data in the skin disease vitiligo. argenx is paying up sharply for a company whose value had already jumped on a single readout.
What it is buying is one drug, FB102, in two small Phase 1b studies. What makes the price interesting is that this exact biological target has already produced one expensive failure, which means argenx is either seeing something the last buyer missed or paying a large premium to relearn an expensive lesson. Both are live possibilities, and the deal is a clean illustration of how large immunology companies now buy growth.
What argenx is actually buying
FB102 is described as a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease. CD122 is a receptor component that helps drive certain immune cells implicated in autoimmune disease, and blocking it is meant to quiet the misdirected immune response that underlies conditions where the body attacks itself.
The appeal of a target like this is breadth. If interfering with CD122 calms autoimmunity in general, one antibody could in principle treat many diseases, vitiligo, celiac, and others, which is the "pipeline in a product" logic that justifies a large upfront price. argenx's own framing leans on exactly that: compelling biology, early clinical validation, and broad potential across autoimmune conditions.
But the evidence base under that breadth is thin at this stage, and the company's release is candid about the shape of it. The proof-of-concept comes from Phase 1b studies, which are small and early. Placebo-controlled efficacy signals in two different diseases at that stage are genuinely encouraging, and they are also exactly the kind of early result that larger trials sometimes fail to reproduce. The first real test of the thesis arrives with Phase 2 celiac data expected in the second half of 2026, after the deal is done.
The premium is a bet on early data holding
Sit with the sequence, because it is the crux of the risk. Forte reported positive vitiligo data on July 9. The stock moved. argenx is now paying an 86% premium over the average price that already incorporated that good news.
That means argenx is not buying a company the market has soured on. It is buying one the market had already re-rated upward on a positive readout, and then paying a large premium on top of the elevated price. The entire logic of that only works if the early data hold up in larger, longer trials. If the Phase 1b signals are real and durable, argenx bought a broad autoimmune franchise before the price fully reflected it. If the signals soften in Phase 2, as early signals sometimes do, argenx will have paid a peak price for a thesis that thinned out.
This is the recurring shape of the bet in early-stage biotech M&A. The acquirer is not paying for proven revenue. It is paying for the probability that a promising early signal becomes a durable one, and the premium is the price of getting in before that question is settled. Get it right and you look prescient. Get it wrong and you paid the most at the moment of maximum optimism.
The graveyard entry that should temper the optimism
Here is the part the celebratory coverage mostly skips, and it is the single most important piece of context. FB102 is not the first attempt to drug CD122, and the previous attempt did not end well.
Incyte acquired a company called Villaris Therapeutics in 2022 specifically to get an anti-CD122 antibody for vitiligo, paying $70 million upfront and committing up to $1.36 billion in milestones. In 2025, Incyte stopped that program. It attributed the decision to broader pipeline prioritization rather than to a specific safety problem, so this is not a case of a target that visibly poisoned patients. But the fact remains that a well-resourced immunology company obtained a CD122 antibody for the same lead indication and chose to walk away from it.
That history cuts in two directions, and honesty requires both. The charitable reading is that Incyte's decision was about its own portfolio, not about CD122's merit, and that FB102 may simply be a better antibody than the one Incyte shelved. Two drugs against the same target are not the same drug, and antibody engineering details matter enormously. The cautionary reading is that when the previous owner of a similar asset quietly discontinues it, and a new buyer then pays a large premium for the same target class, the burden is on the new buyer to explain what is different, and "our molecule is better" is a claim that only Phase 2 and Phase 3 data can actually support.
argenx may well be right. It has a strong record of picking and developing immunology assets. But a target with a discontinuation already on its record is a target where confident optimism should be discounted, because the field has one data point suggesting this is harder than it looks.
Why argenx is doing this now
The strategic motivation is straightforward and, unlike the science, not in much doubt. argenx has become one of the most valuable companies in biotech, with a market capitalization above $56 billion, on the strength of essentially one product: Vyvgart, an immunology drug approved for myasthenia gravis and a second nerve condition, which generated more than $4 billion in 2025 and is on pace to exceed that in 2026.
A company that valuable resting on a single franchise has an obvious vulnerability, and its management knows it. The Forte deal is a diversification move, an attempt to build a second pillar before anything threatens the first. The urgency behind it is easier to understand in light of a specific setback: late last year argenx ended a late-stage trial of Vyvgart in an eye disease, a reminder that even a successful drug's expansion is not guaranteed. When your growth depends on widening the label of one product, and one of those widenings fails, buying a second product with broad potential becomes more attractive, and you may be willing to pay more for it.
That context does not make the price right or wrong. It explains the motivation, and it also hints at why argenx might have been willing to stretch on the premium. A buyer that needs a second franchise is a more motivated buyer than one that merely wants one, and motivated buyers pay more.
How to read it
The deal is a bet with a clearly defined payoff structure, and the honest summary is to state both branches rather than pick one. If FB102's early efficacy in vitiligo and celiac holds up in larger trials, argenx will have acquired a potentially broad autoimmune franchise at a price that looks cheap in hindsight, and diversified away from single-product risk in the process. If the early signals fade, which happens often enough at this stage that it cannot be dismissed, argenx will have paid an 86% premium at the moment of peak optimism for a target that already has one company's discontinuation on its record.
The tell that separates those outcomes is not available yet. It arrives with the Phase 2 celiac data in the second half of 2026, which is the first properly powered test of whether the biology is as broad as the price assumes. Until then, the deal rests on the same thing every early-stage acquisition rests on: the hope that a small, encouraging signal is the beginning of something real rather than a result that looked better early than it turned out to be. argenx has paid for the optimistic version. Whether it got a franchise or a lesson is a question the data have not yet answered.
Primary sources
- argenx's press release for the $77-per-share, roughly $2.2 billion terms, the FB102 anti-CD122 first-in-class description, the clinical proof-of-concept in vitiligo and celiac disease, the 86% premium to the volume-weighted average price since the July 9 vitiligo data, the tender-offer structure, and the Hart-Scott-Rodino condition.
- BioPharma Dive for the 41% premium to Friday's close, the third-quarter expected close, argenx's market capitalization above $56 billion, and Vyvgart's 2025 sales above $4 billion and 2026 pace.
- European Biotechnology Magazine for the Incyte-Villaris 2022 acquisition of an anti-CD122 antibody, the $70 million upfront and up to $1.36 billion in milestones, Incyte's 2025 discontinuation attributed to pipeline prioritization without a stated safety problem, and the caution that the small Phase 1b results may not hold in larger trials with Phase 2 celiac data due in the second half of 2026.
- Yahoo Finance for the diversification rationale, the discontinued late-stage Vyvgart eye-disease trial, and the unanimous board approvals.
- The SEC 8-K exhibit and GuruFocus for confirming deal terms and the cash-tender structure.